Tirabrutinib + Rituximab + Temozolomide
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Primary Central Nervous System Lymphoma
Conditions
Relapsed/Refractory Primary Central Nervous System Lymphoma
Trial Timeline
Mar 1, 2026 → Dec 1, 2029
NCT ID
NCT07104032About Tirabrutinib + Rituximab + Temozolomide
Tirabrutinib + Rituximab + Temozolomide is a phase 3 stage product being developed by Ono Pharmaceutical for Relapsed/Refractory Primary Central Nervous System Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07104032. Target conditions include Relapsed/Refractory Primary Central Nervous System Lymphoma.
What happened to similar drugs?
0 of 9 similar drugs in Relapsed/Refractory Primary Central Nervous System Lymphoma were approved
Approved (0) Terminated (1) Active (8)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07104032 | Phase 3 | Recruiting |
Competing Products
20 competing products in Relapsed/Refractory Primary Central Nervous System Lymphoma